Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test
Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in nearly half of the patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
